Osphena (Ospemifene) Patent Expiration, LOE Window & CMS Spending

Osphena (Ospemifene) by Duchesnay: FDA Orange Book LOE 2028-07-09, 0 AB generics, $8.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDuchesnay
FDA Application & PathwayN203505 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-07-09
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8.2M
2024 Medicare Part D Spend$7.8M
2024 Medicaid Spend$353K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel